What Kailera Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 5 |
| Sells | 0 | 0 |
| Total trades | 1 | 15 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 38,094 | 120,004,464 |
| Disposed | 0 | 0 |
| Net activity | +38,094 | +120,004,464 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Renaud Ronald C Jr | CEO & President | Jun 09 | Exercise / conversion · M | +38,094 | $5.25 | +$200K | 38,094 |
| Kaplan Andrew T. | Director | Apr 20 | Open-market buy · P | +8,398,438 | $16.00 | +$134M | 26,255,581 |
| Kaplan Andrew T. | Director | Apr 20 | Derivative Conversion · C | +17,857,143 | — | — | 17,857,143 |
| Bain Capital Life Sciences Investors, Llc | 10% owner | Apr 20 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 22,583,268 |
| Bain Capital Life Sciences Investors, Llc | 10% owner | Apr 20 | Derivative Conversion · C | +4,145,768 | — | — | 21,020,768 |
| Bain Capital Life Sciences Investors, Llc | 10% owner | Apr 20 | Derivative Conversion · C | +16,875,000 | — | — | 16,875,000 |
| Koppel Adam | Director | Apr 20 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 22,583,268 |
| Koppel Adam | Director | Apr 20 | Derivative Conversion · C | +4,145,768 | — | — | 21,020,768 |
| Koppel Adam | Director | Apr 20 | Derivative Conversion · C | +16,875,000 | — | — | 16,875,000 |
| Bain Capital Investors Llc | 10% owner | Apr 20 | Open-market buy · P | +8,398,438 | $16.00 | +$134M | 26,255,581 |
| Bain Capital Investors Llc | 10% owner | Apr 20 | Derivative Conversion · C | +17,857,143 | — | — | 17,857,143 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Apr 20 | Derivative Conversion · C | +2,034,133 | — | — | 2,034,133 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Apr 20 | Derivative Conversion · C | +9,477,719 | — | — | 9,477,719 |
| Rtw INVESTMENTS, Lp | 10% owner | Apr 20 | Open-market buy · P | +500,000 | $16.00 | +$8M | 10,776,820 |
| Rtw INVESTMENTS, Lp | 10% owner | Apr 20 | Derivative Conversion · C | +10,276,820 | — | — | 10,276,820 |
Loading...